Skip to content
Search

Latest Stories

Bumrah rises to second, Kohli top-ranked batsmen in T20

India pacer Jasprit Bumrah has risen to second in the latest ICC Twenty20 rankings while skipper Virat Kohli has retained the top spot in the batsmen's list.

There is no change in the top three of the all-rounders' table which is headed by Shakib Al Hasan of Bangladesh.


Pakistan's ICC Champions Trophy-winning side's member Imad Wasim has become the number-one ranked T20 bowler after South Africa's Imran Tahir lost ground following the conclusion of the series against England.

In the latest rankings for T20 bowlers, which was updated a day after England beat South Africa 2-1, Tahir has slipped two places after he managed only one wicket in two matches.

His drop to third means Imad has surged to the top for the first time in his career, with Bumrah rising to second.

In the batting table, Kohli, Aaron Finch of Australia and Kane Williamson of New Zealand have retained the top three positions.

However, AB de Villiers and Jason Roy are the biggest movers following the just-concluded series.

De Villiers, who was the leading run-getter in the series with 146 runs, has returned to the top 20 in 20th position after rising 12 places, while Roy's series aggregate of 103 runs has helped him achieve a career-high 25th position after jumping 26 places.

In the team rankings, England has moved into outright second position. It had started the series level with Pakistan on 121 points, but has now moved to 123 points to trail number-one ranked New Zealand by two points.

In contrast, South Africa has dropped one point to join Australia on 110 points. However, it is ranked ahead of Australia by a fraction of a point, and occupies the sixth position.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less